Rabbit anti-IL-6 receptor Recombinant Antibody (Unconjugated), suitable for ELISA, Block.
Background Info:
This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques. Tocilizumab can be used in ELISA assays and is able to inhibit the growth of IL-6-dependent tumor cell lines (to the same extent as the original AUK12-2mouse antibody) - inhibits sIL-6R and mIL-6R-mediated signaling.
Product Type:
Antibody
Antibody Type:
Recombinant
Format:
Liquid. PBS with 0.02% Proclin 300.
Host Animal:
Rabbit
Species Reactivity:
Human
Immunogen:
This antibody was prepared by CDR grafting of mouse AUK 12-20 antibody onto a human framework regions.
Applications:
Block,ELISA
Clone number:
rhPM-1 (Tocilizumab)
Antibody Isotype:
IgG, kappa
Application Details:
Tocilizumab can be used in ELISA assays and is able to inhibit the growth of IL-6-dependent tumor cell lines (to the same extent as the original AUK12-20 mouse antibody) - inhibits sIL-6R and mIL-6R-mediated signaling.
Alternative Names:
IL6R; MRA; atlizumab
Biosensis Brand:
Biosensis®
Conjugate:
Unconjugated
Shelf Life:
Store at 2-8?C for up to 3 months. For longer storage, aliquot and store at -20?C for up to 12 months.
Use:
For research use only.
Concentration:
1 mg/mL
Specificity:
Tocilizumab binds specifically to both the membrane bound and soluble forms of human IL-6R. The IL6 receptor is a protein complex consisting of an IL-6 receptor subunit (IL6R) and interleukin 6 signal transducer Glycoprotein 130. Interleukin 6 (IL6) is a potent pleiotropic cytokine that regulates cell growth and differentiation and plays an important role in immune response.
This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques. Basiliximab is derived from the murine anti-Tac antibody. For the clinically used format, the variable regions from this antibody were grafted onto the sequence of the human IgG1 constant regions. Basiliximab binding to CD25 competitively blocks the interaction of IL-2R with its ligand IL-2 on the surface of T cells. Blocking this interaction prevents T cell replication and T cell-mediated B cell activation. Basiliximab binding suppresses the immune system inhibits the pathway activating the cellular immune response to allograft rejection. IL-2 signalling suppression can additionally prevent acute graft-versus-host disease, autoimmune disorders and malignancies such as T cell leukemias (Binder et al, 2007). Basiliximab has also been used in FC, IF, IHC and WB studies, which enables the detection of CD25.
Product Type:
Antibody
Antibody Type:
Recombinant
Format:
Liquid. PBS with 0.02% Proclin 300.
Host Animal:
Rabbit
Species Reactivity:
Human,Primate
Immunogen:
Basiliximab was prepared by immunizing BALB/c mice with CTC 16 cells.
Applications:
Block,FC,ICC,IHC,WB
Clone number:
Basiliximab
Antibody Isotype:
IgG, kappa
Application Details:
Basiliximab is derived from the murine anti-Tac antibody. For the clinically used format, the variable regions from this antibody were grafted onto the sequence of the human IgG1? constant regions. Basiliximab binding to CD25 competitively blocks the interaction of IL-2R with its ligand IL-2 on the surface of T cells. Blocking this interaction prevents T cell replication and T cell-mediated B cell activation. Basiliximab binding suppresses the immune system inhibits the pathway activating the cellular immune response to allograft rejection. IL-2 signalling suppression can additionally prevent acute graft-versus-host disease, autoimmune disorders and malignancies such as T cell leukemias (Binder et al, 2007). Basiliximab has also been used in FC, IF, IHC and WB studies, which enables the detection of CD25.
Store at 2-8?C for up to 3 months. For longer storage, aliquot and store at -20?C for up to 12 months.
Use:
For research use only.
Concentration:
1 mg/mL
Specificity:
Basiliximab recognises the human IL-2R and binds to the epitope (116)ERIYHFV(122) within the extracellular domain of the CD25 subunit binding is abolished when 2 or more residues within the epitope are mutated. This epitope overlaps with the interaction site of CD25 and IL-2. CD25 is found in the high-affinity IL-2R (???c) T cells only express CD25 upon activation. IL-2 binding to IL-2R on T cells modulates proliferation and differentiation.
This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques.
Product Type:
Antibody
Antibody Type:
Recombinant
Format:
Liquid. PBS with 0.02% Proclin 300.
Host Animal:
Rabbit
Species Reactivity:
Human,Primate
Immunogen:
Cultured T-cells derived from a patient with Mycosis fungoides.
Store at 2-8?C for up to 3 months. For longer storage, aliquot and store at -20?C for up to 12 months.
Use:
For research use only.
Concentration:
1 mg/mL
Specificity:
Binds to p55 chain of IL2R on human T cells, Tac antigen, which is expressed on T cells activated by mitogens, soluble antigens, and alloantigens but not on resting T cells, thymocytes, B cells, monocytes, activated B cells, leukemic T cell blasts from patients with acute lymphoblastic leukemia, and long-term T cell lines.
Human anti-Interleukin 6 receptor (IL-6R) Recombinant Antibody (Unconjugated), suitable for ELISA, Block.
Background Info:
NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. Tocilizumab can be used in ELISA assays and is able to inhibit the growth of IL-6-dependent tumor cell lines (to the same extent as the original AUK12-2mouse antibody) - inhibits sIL-6R and mIL-6R-mediated signaling.
Product Type:
Antibody
Antibody Type:
Recombinant
Format:
Liquid. PBS with 0.02% Proclin 300.
Host Animal:
Human
Species Reactivity:
Human
Immunogen:
This antibody was prepared by CDR grafting of mouse AUK 12-20 antibody onto a human framework regions.
Applications:
Block,ELISA
Clone number:
rhPM-1 (Tocilizumab)
Antibody Isotype:
IgG1, kappa
Application Details:
Tocilizumab can be used in ELISA assays and is able to inhibit the growth of IL-6-dependent tumor cell lines (to the same extent as the original AUK12-20 mouse antibody) - inhibits sIL-6R and mIL-6R-mediated signaling.
Alternative Names:
IL6R; MRA; atlizumab
Biosensis Brand:
Biosensis®
Conjugate:
Unconjugated
Shelf Life:
Store at 2-8?C for up to 3 months. For longer storage, aliquot and store at -20?C for up to 12 months.
Use:
For research use only.
Concentration:
1 mg/mL
Specificity:
Tocilizumab binds specifically to both the membrane bound and soluble forms of human IL-6R. The IL6 receptor is a protein complex consisting of an IL-6 receptor subunit (IL6R) and interleukin 6 signal transducer Glycoprotein 130. Interleukin 6 (IL6) is a potent pleiotropic cytokine that regulates cell growth and differentiation and plays an important role in immune response.
Human anti-Interleukin-2 receptor (IL-2R) Recombinant Antibody (Unconjugated), suitable for FC, Block, ICC, IHC, WB.
Background Info:
NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This is a chimeric antibody created for improved compatibility with existing reagents, assays and techniques. Basiliximab is derived from the murine anti-Tac antibody. For the clinically used format, the variable regions from this antibody were grafted onto the sequence of the human IgG1 constant regions. Basiliximab binding to CD25 competitively blocks the interaction of IL-2R with its ligand IL-2 on the surface of T cells. Blocking this interaction prevents T cell replication and T cell-mediated B cell activation. Basiliximab binding suppresses the immune system inhibits the pathway activating the cellular immune response to allograft rejection. IL-2 signalling suppression can additionally prevent acute graft-versus-host disease, autoimmune disorders and malignancies such as T cell leukemias (Binder et al, 2007). Basiliximab has also been used in FC, IF, IHC and WB studies, which enables the detection of CD25.
Product Type:
Antibody
Antibody Type:
Recombinant
Format:
Liquid. PBS with 0.02% Proclin 300.
Host Animal:
Human
Species Reactivity:
Human,Primate
Immunogen:
Basiliximab was prepared by immunizing BALB/c mice with CTC 16 cells.
Applications:
Block,FC,ICC,IHC,WB
Clone number:
Basiliximab
Antibody Isotype:
IgG1, kappa
Application Details:
Basiliximab is derived from the murine anti-Tac antibody. For the clinically used format, the variable regions from this antibody were grafted onto the sequence of the human IgG1? constant regions. Basiliximab binding to CD25 competitively blocks the interaction of IL-2R with its ligand IL-2 on the surface of T cells. Blocking this interaction prevents T cell replication and T cell-mediated B cell activation. Basiliximab binding suppresses the immune system inhibits the pathway activating the cellular immune response to allograft rejection. IL-2 signalling suppression can additionally prevent acute graft-versus-host disease, autoimmune disorders and malignancies such as T cell leukemias (Binder et al, 2007). Basiliximab has also been used in FC, IF, IHC and WB studies, which enables the detection of CD25.
Store at 2-8?C for up to 3 months. For longer storage, aliquot and store at -20?C for up to 12 months.
Use:
For research use only.
Concentration:
1 mg/mL
Specificity:
Basiliximab recognises the human IL-2R and binds to the epitope (116)ERIYHFV(122) within the extracellular domain of the CD25 subunit binding is abolished when 2 or more residues within the epitope are mutated. This epitope overlaps with the interaction site of CD25 and IL-2. CD25 is found in the high-affinity IL-2R (???c) T cells only express CD25 upon activation. IL-2 binding to IL-2R on T cells modulates proliferation and differentiation.
Store at 2-8?C for up to 3 months. For longer storage, aliquot and store at -20?C for up to 12 months.
Use:
For research use only.
Concentration:
1 mg/mL
Specificity:
Binds to p55 chain of IL2R on human T cells, Tac antigen, which is expressed on T cells activated by mitogens, soluble antigens, and alloantigens but not on resting T cells, thymocytes, B cells, monocytes, activated B cells, leukemic T cell blasts from patients with acute lymphoblastic leukemia, and long-term T cell lines.
X
We use cookies to help personalise and improve your web experience.
By using our website you consent to our use of cookies, some of which may have already been set on your device.
View our Cookie Policy to learn more.
